North American region is leading the GLP-1 agonists market.
& Sato, R
Cardiovasc Diabetol 17:153 Chilton R, Tikkanen I, Cannon CP et al (2015) Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
The dominant companies leverage extensive R&D capabilities, large-scale production facilities, and long-term partnerships with cosmetic, pharmaceutical, and nutraceutical brands
If you need a new shampoo, reach for the NanoSkin Hyper Suds
Venom compounds are fast acting, very potent, and very specific, said Mand Holford, a chemical biologist at Hunter College who was not involved in the study, as per The Scientist